ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up